Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LifeTech Scientific Corporation ( (HK:1302) ) has issued an update.
LifeTech Scientific Corporation announced the successful completion of two-year follow-up results for its Phase II and Phase III clinical studies of the IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System. The studies demonstrated that the IBS® Coronary Scaffold achieved non-inferiority in primary endpoints compared to existing solutions, with low rates of thrombotic events. This positions the product as a competitive alternative to current drug-eluting metal stents, receiving positive feedback from cardiovascular experts at the Transcatheter Cardiovascular Therapeutics 2025 conference.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation operates in the medical technology industry, focusing on the development of innovative medical devices. The company specializes in bioresorbable coronary scaffold systems, which are designed to improve cardiovascular health outcomes.
Average Trading Volume: 34,567,160
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.29B
For a thorough assessment of 1302 stock, go to TipRanks’ Stock Analysis page.